Essilor Luxottica announced the purchase of RetinAI, a company specialized in artificial intelligence and data management in ophthalmology sector. The strengthening continues in this way health technology sector of the group that will present later today the results of the third quarter with the estimates of Bloomberg Revenues rose to €6,75 billion, up 8,5% at constant currency. Shares on the Paris Stock Exchange are trading up 1,60%.
“In the last year alone, we have made several bold moves in medical technology, all with the goal of creating the most complete and digitalized patient journey,” said Francesco Milleri, Chairman and CEO of EssilorLuxottica. “RetinAI will add incredible value.” This strengthens the group's position in clinical and diagnostic innovation, with the'software integration advanced, machine learning and computer vision capable of improve medical, research, and pharmaceutical processes.
Ikerian AG, the company operating with the RetinAI brand , has developed tools for collecting and processing data from retinal images in the healthcare technology sector, EssilorLuxottica commented. RetinAI specializes in the processing and analysis of retinal images and biometric data at scale. Its flagship platform, RetinAI Discovery, è FDA approved A US-based, CE-certified technology ecosystem that enables the monitoring of eye diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma, enabling faster and more targeted diagnoses. The company's solutions are already being used by pharmaceutical companies and international research centers to accelerate clinical trials and the development of new treatments.
